Difference between revisions of "G2E3-AS1"
| Line 8: | Line 8: | ||
===RefSeq(supplied by NCBI)=== | ===RefSeq(supplied by NCBI)=== | ||
XR_001750710 | XR_001750710 | ||
| − | + | [[File:The expression levels of CAT266, CAT1297 and CAT1647 in other urological tissue types.png|right|thumb|400px|'''The expression levels of CAT266, CAT1297 and G2E3-AS1(CAT1647) in other urological tissue types'''<ref name="ref1" />]] | |
| − | |||
| − | [[File:The expression levels of CAT266, CAT1297 and CAT1647 in other urological tissue types.png|right|thumb|400px|'''The expression levels of CAT266, CAT1297 and CAT1647 in other urological tissue types'''<ref name="ref1" />]] | ||
===Disease=== | ===Disease=== | ||
Bladder cancer | Bladder cancer | ||
Latest revision as of 03:27, 27 January 2018
Contents
Annotated Information
Approved Symbol
G2E3-AS1 (G2E3 antisense RNA 1)
Synonyms
CAT1647
Chromosome
14q12
RefSeq(supplied by NCBI)
XR_001750710
The expression levels of CAT266, CAT1297 and G2E3-AS1(CAT1647) in other urological tissue types[1]
Disease
Bladder cancer
Characteristics
G2E3-AS1 is significantly enriched in the cytoplasmic fraction. [1]
Function
Knockdown G2E3-AS1 activate apoptotic pathways leading to decrease in migration capacity of bladder cancer cells.[1]
Expression
G2E3-AS1 is up-regulated in bladder cancer. [1] Expression levels of G2E3-AS1 is found to be significantly higher in high grade bladder cancer (p = 0.027).[1]
Labs working on this lncRNA
- Department of Urology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands [1]
